Charla Andrews

10.8k total citations · 2 hit papers
30 papers, 4.8k citations indexed

About

Charla Andrews is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Charla Andrews has authored 30 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 13 papers in Epidemiology and 13 papers in Immunology. Recurrent topics in Charla Andrews's work include HIV Research and Treatment (12 papers), Hepatitis B Virus Studies (7 papers) and Viral Infections and Outbreaks Research (5 papers). Charla Andrews is often cited by papers focused on HIV Research and Treatment (12 papers), Hepatitis B Virus Studies (7 papers) and Viral Infections and Outbreaks Research (5 papers). Charla Andrews collaborates with scholars based in United States, Netherlands and Thailand. Charla Andrews's co-authors include David D. Ho, Richard A. Koup, Jeffrey T. Safrit, Yaming Cao, Charles Farthing, Gavin X. McLeod, William Borkowsky, Martin Hirsch, Robert T. Schooley and T R Rota and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Charla Andrews

30 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

1994 2.0k citations Richard A. Koup, Jeffrey T. Safrit et al. profile →
Isolation of HTLV-III from Cerebrospinal Fluid and Neural Tissues of Patients with Neurologic Syndromes Related to the Acquired Immunodeficiency Syndrome

1985 836 citations David D. Ho, T R Rota et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charla Andrews United States	20	3.1k	2.2k	2.0k	1.4k	634	30	4.8k
Michael Murphey‐Corb United States	41	3.8k 1.2×	2.1k 1.0×	1.9k 1.0×	2.0k 1.5×	762 1.2×	130	5.7k
Jörg Schüpbach Switzerland	35	2.7k 0.9×	1.7k 0.8×	2.3k 1.2×	1.3k 0.9×	536 0.8×	100	5.2k
Silvija I. Staprans United States	36	3.3k 1.1×	2.3k 1.1×	1.6k 0.8×	1.8k 1.3×	614 1.0×	60	4.9k
Donald L. Sodora United States	40	3.8k 1.2×	2.9k 1.3×	1.6k 0.8×	1.9k 1.4×	478 0.8×	90	5.4k
James Blanchard United States	36	3.1k 1.0×	2.4k 1.1×	2.2k 1.1×	1.6k 1.2×	676 1.1×	124	5.2k
Gabriella Scarlatti Italy	37	3.7k 1.2×	2.0k 0.9×	2.6k 1.3×	945 0.7×	653 1.0×	130	4.8k
Meredith A. Simon United States	31	2.5k 0.8×	2.2k 1.0×	1.1k 0.6×	1.2k 0.9×	683 1.1×	68	4.5k
Margreet Bakker Netherlands	35	2.4k 0.8×	861 0.4×	2.3k 1.2×	1.0k 0.7×	731 1.2×	128	4.6k
Agegnehu Gettie United States	43	5.2k 1.7×	3.2k 1.5×	2.7k 1.4×	2.0k 1.5×	685 1.1×	113	6.8k
Patricia N. Fultz United States	35	3.4k 1.1×	1.5k 0.7×	1.6k 0.8×	1.7k 1.2×	604 1.0×	106	4.3k

Countries citing papers authored by Charla Andrews

Since Specialization

Citations

This map shows the geographic impact of Charla Andrews's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charla Andrews with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charla Andrews more than expected).

Fields of papers citing papers by Charla Andrews

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charla Andrews. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charla Andrews. The network helps show where Charla Andrews may publish in the future.

Co-authorship network of co-authors of Charla Andrews

This figure shows the co-authorship network connecting the top 25 collaborators of Charla Andrews. A scholar is included among the top collaborators of Charla Andrews based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charla Andrews. Charla Andrews is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pitisuttithum, Punnee, Sorachai Nitayaphan, Suwat Chariyalertsak, et al.. (2014). RV306, an Evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections. AIDS Research and Human Retroviruses. 30(S1). A264–A264. 4 indexed citations

Prentice, Heather A., Philip K. Ehrenberg, Aviva Geretz, et al.. (2014). HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics. 66(5). 299–310. 10 indexed citations

Ledgerwood, Julie E., Pamela Costner, Niraj M. Desai, et al.. (2010). A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 29(2). 304–313. 141 indexed citations

Rao, Srinivas S., et al.. (2009). A gene-based avian influenza vaccine in poultry. Poultry Science. 88(4). 860–866. 11 indexed citations

Martin, Julie E., Mark K. Louder, Ingelise J. Gordon, et al.. (2008). A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 26(50). 6338–6343. 197 indexed citations

Martin, Julie E., Theodore C. Pierson, Ingelise J. Gordon, et al.. (2007). A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. The Journal of Infectious Diseases. 196(12). 1732–1740. 131 indexed citations

Catanzaro, Andrew, Mario Roederer, Richard A. Koup, et al.. (2007). Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 25(20). 4085–4092. 96 indexed citations

Tavel, Jorge A., Julie E. Martin, Mary E. Enama, et al.. (2007). Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(5). 601–605. 44 indexed citations

Graham, Barney S., Richard A. Koup, Mario Roederer, et al.. (2006). Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine. The Journal of Infectious Diseases. 194(12). 1650–1660. 151 indexed citations

10.

Sheets, Rebecca, Judith A. Stein, T. Scott Manetz, et al.. (2006). Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts. Toxicological Sciences. 91(2). 610–619. 76 indexed citations

11.

Sheets, Rebecca, Judith A. Stein, T. Scott Manetz, et al.. (2006). Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-Inserts. Toxicological Sciences. 91(2). 620–630. 36 indexed citations

12.

Martin, Julie E., Nancy J. Sullivan, Mary E. Enama, et al.. (2006). A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. Clinical and Vaccine Immunology. 13(11). 1267–1277. 168 indexed citations

13.

Andrews, Charla & Richard A. Koup. (1996). The immunopathology of HIV infection. Journal of Antimicrobial Chemotherapy. 37(suppl B). 13–25. 6 indexed citations

14.

Safrit, Jeffrey T., et al.. (1994). A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients.. The Journal of Immunology. 153(8). 3822–3830. 40 indexed citations

15.

Safrit, Jeffrey T., Charla Andrews, Tuofu Zhu, David D. Ho, & R Koup. (1994). Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope.. The Journal of Experimental Medicine. 179(2). 463–472. 141 indexed citations

16.

Safrit, Jeffrey T., Michael Fung, Charla Andrews, et al.. (1993). hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS. 7(1). 15–22. 79 indexed citations

17.

Andrews, Charla, K. V. Shah, Richard Daniel, M. S. Hirsch, & R H Rubin. (1988). A Serological Investigation of BK Virus and JC Virus Infections in Recipients of Renal Allografts. The Journal of Infectious Diseases. 158(1). 176–181. 121 indexed citations

18.

Andrews, Charla, John L. Sullivan, Doreen B. Brettler, et al.. (1987). Isolation of human immunodeficiency virus from hemophiliacs: Correlation with clinical symptoms and immunologic abnormalities. The Journal of Pediatrics. 111(5). 672–677. 20 indexed citations

19.

Ho, David D., T R Rota, Robert T. Schooley, et al.. (1987). Isolation of HTLV-III from CSF and neural tissues of patients with AIDS-related neurological syndromes. Annales de l Institut Pasteur Virologie. 138(1). 137–144. 7 indexed citations

20.

Andrews, Charla, K. V. Shah, R H Rubin, & Martin Hirsch. (1982). BK Papovavirus Infections in Renal Transplant Recipients: Contribution of Donor Kidneys. The Journal of Infectious Diseases. 145(2). 276–276. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact